Jefferies Financial Group’s Amicus Therapeutics FOLD Stock Holding History

Jefferies Financial Group’s Portfolio FOLD Stock Details FOLD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$583K	Sell	40,300 -125,185	-76%	-$1.79M	﹤0.01%	1143
2025 Q4	$2.36M	Hold	165,485	–	–	0.01%	743
2025 Q3	$1.3M	Sell	165,485 -58,315	-26%	-$415K	0.01%	778
2025 Q2	$1.28M	Buy	223,800 +35,903	+19%	+$232K	0.01%	649
2025 Q1	$1.53M	Buy	+187,897	New	+$1.74M	0.01%	654
2024 Q1	–	Sell	-29,494	Closed	-$419K	–	1742
2023 Q4	$419K	Sell	29,494 -24,279	-45%	-$276K	﹤0.01%	1286
2023 Q3	$654K	Sell	53,773 -38,512	-42%	-$497K	0.01%	964
2023 Q2	$1.16M	Buy	+92,285	New	+$1.1M	0.01%	860

Other funds holding FOLD

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

PCM

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

GCL

Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

Jefferies Financial Group's FOLD Position: Q1 2026 in Review

Jefferies Financial Group reduced its Amicus Therapeutics (FOLD) stake by 76% in Q1 2026, selling an estimated $1.79M and leaving 40,300 shares worth $583K. The position accounts for ﹤0.01% of the portfolio, ranked #1143.

Jefferies Financial Group first reported a position in FOLD in Q2 2023 and has held it in 8 quarters since. The position peaked at $2.36M in Q4 2025. 298 funds tracked by Wall St. Rank hold FOLD as of Q1 2026.

Jefferies Financial Group held 40,300 shares of Amicus Therapeutics worth $583K as of Q1 2026.
Jefferies Financial Group sold 125,185 Amicus Therapeutics shares in Q1 2026, an estimated $1.79M.
Amicus Therapeutics made up ﹤0.01% of Jefferies Financial Group's portfolio in Q1 2026, its #1143 holding.
Jefferies Financial Group first reported a position in Amicus Therapeutics in Q2 2023 and has held it in 8 quarters since.
Jefferies Financial Group's Amicus Therapeutics position peaked at $2.36M in Q4 2025.
298 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q1 2026.

Based on Jefferies Financial Group's 13F filing for Q1 2026, filed 8 May 2026.